

Master MUsT elements

Luke Oh, Ph.D.

Clinical Pharmacology Reviewer, DIIP Office of Clinical Pharmacology, CDER, FDA

Topical Drug Development – Evolution of Science and Regulatory Policy II July 23 - 24, 2020



FDA

Disclaimer

The views and opinions presented here represent those of the speaker and should not be considered to represent advice or guidance on behalf of the U.S. Food and Drug Administration.

Agenda

- Background
- MUsT key elements
- MUsT program for Sunscreen
- Master protocol
- Regulatory action & advice
- Summary

Background



- What is MUsT?
 - Maximal Use Trial program enables the assessment of systemic concentrations of a topically applied drug product under maximal use conditions.
- Why is MUsT important?
 - For topical OTC products such as sunscreens and antiseptics, safety concerns are critical as OTC drug products are used by a large population with a wide age range.
 - Once an active ingredient is included in the monograph category I (GRASE), many different formulations can be developed and marketed without additional studies.
- Why do we need Master protocol?
 - Consistency and clarity in data interpretation.
 - Time and resource effective for drug development

"Standard Design Elements" of MUsT under OTC FDA monograph*

- ✓ Frequency of dosing
- ✓ Duration of dosing
- ✓ Use of highest proposed strength
- \checkmark Total involved surface area to be treated at one time
- ✓ Amount applied per square centimeter (area)
- ✓ Method of application/site preparation

* Final Guidance for Industry: Maximal usage trials for topically applied active ingredients being considered for inclusion in an Over-The-Counter monograph: Study elements and consideration (May 2019)


Common Key Elements



- Demographics of subjects
 - Number of subjects representing general US demographics across sex, ages, and races.
- Body surface area
 - Maximal body surface area per topical application that is consistent with proposed use.
- Frequency of application
 - Maximal number of uses per day (over an 8-hour period)
- Treatment duration
 - Maximal duration of usage or time to reach steady state


Skin damage by ultra-violet (UV) rays and Benefits of sunscreen














(Gordon and Brieva, Unilateral Dermatoheliosis, N Engl J Med 2012; 366:e25)



Benefits of Sunscreen

- Decrease in skin aging
- Decrease in sunburn
- May reduce potential risks of skin cancer

Sunscreen Active Ingredients





FDA Proposes Sunscreen Regulation Changes February 2019

The U.S. Food and Drug Administration (FDA) regulates sunscreens to ensure they meet safety and effectiveness standards. To improve the quality, safety, and effectiveness of sunscreens, FDA issued a proposed rule that describes updated proposed requirements for sunscreens. Given the recognized public health benefits of sunscreen use. Americans should continue to use broad spectrum sunscreen with SPF 15 or higher with other sun protective measures as this important rulemaking effort moves forward.

Highlights of FDA's Proposals



Sunscreen active Ingredient safety and effectiveness Two ingredients (zinc oxide and titanium dioxide) are proposed to be safe and effective for sunscreen use and two (aminobenzoic acid (PABA) and trolamine salicylate) are proposed as not safe and effective for sunscreen use. FDA proposes that it needs more safety information for the remaining 12 sunscreen ingredients (cinoxate, dioxybenzone, ensulizole, homosalate, meradimate, octinoxate, octisalate, octocrylene, padimate O. sulisobenzone, oxybenzone, avobenzone),



FDA

Sunscreen dosage forms unscreen sprays, oils, lotions, creams, gels, outters, pastes, ointments, and sticks are proposed as safe and effective. FDA proposes that it needs more data for inscreen powders

æ ٥ *

New proposed sun protection factor (SPF) and broad spectrum requirements Raise the maximum proposed labeled SPF

from SPF 50+ to SPF 60+ Require any sunscreen SPF 15 or higher to be broad spectrum

Require for all broad spectrum products SPF 15 and above, as SPF increases, broad spectrum protection increases

New proposed label requirements

- Include alphabetical listing of active ingredients on the front panel
- Require sunscreens with SPF below 15 to include "See Skin Cancer/Skin Aging alert" on the front panel
- Require font and placement changes to ensure SPF, broad spectrum, and water resistance statements stand out

Sunscreen-insect repellent combination products proposed not safe and effective



www.fda.gov

Category I (GRASE) Zinc Oxide **Titanium Dioxide**

Category II (Non-GRASE) Aminobenzoic acid (PABA) **Trolamine salicylate**

Category III (Insufficient data for GRASE determination)

1	Avobenzone	
2	Oxybenzone	
3	Ensulizole	
4	Homosalate	
5	Meradimate	
6	Octinoxate	
7	Octisalate	
8	Octocrylene	
9	Padimate O	
10	Sulisobenzone	L
11	Dioxybenzone	
12	Cinoxate	

erred

Sunscreen Final Rule Deferral




- Sunscreen final rule has been deferred till Nov. 29. 2020
- The sunscreen industry has submitted the deferral request of 8 active ingredients in Category III.
 - The industry needs to provide a pharmacokinetic (PK) assessment of active ingredients following repeated topical applications under maximal use conditions.
 - Depending on the level of systemic exposure of active ingredients, additional nonclinical studies may be necessary to support the systemic safety of the active ingredients.
 - The FDA is working with the industry to set the Master protocol with standardization of key elements.




Dermal absorption of sunscreen

- Sunscreen ingredients were found in systemic circulation and tissue in humans (Schlumpf, 2010; Krause, 2012, ..., etc)
- In vivo permeation studies show detectable systemic exposure of a sunscreen ingredient following topical application of sunscreen (Janjua, 2008; Gonzalez, 2006; Gulson, 2012, ...,etc)







(Gulson et al, 2012)



Insufficient dermal absorption data in literature

- Common issues in publication
 - Extemporaneous formulations
 - Sub-maximal use conditions
- Recommended criteria of maximal use conditions
 - Application every 2 hours 4 times a day
 - Duration to reach steady state (to be informed by a pilot study)
 - Body surface area minimum 75%
 - Dose per topical application: 2 mg/cm²




Considerations for MUsT



Considerations for MUsT







Sunscreen Pilot MUsT study design

Pilot MUsT study design			
Population	Healthy subjects		
Dosing regimen	Every 2 hours (4 times per day)		
Dose	2 mg/cm ²		
BSA	75%		
PK sample collection	To-be-determined based on characteristics of ingredient		

- A pilot study is to obtain initial PK data to design the confirmatory pivotal study.
- The subject number should be able to address the anticipated inter-subject and intra-subject variability.
- At least 4 market-image formulations should be tested including one formulation with permeation enhancer.
- PK sample collection needs to adequately capture the Cmax, Tmax, and the entire concentration-versus-time profile.

Sunscreen Pivotal MUsT study design



Pivotal MUsT study design		
Population	N healthy subjects	
Dosing regimen	Every 2 hours (4 times per day)	
Dose	2 mg/cm ²	
Treatment duration	5 days or to reach steady-state	
BSA	75%	
PK sample collection	To-be-determined based on pilot study results	

- Pivotal MUsT study should be conducted in a sufficiently large number of subjects given the large target population and variation in skin permeation within it
- Elements including dose, dosing regimen, and BSA are standardized. The current label recommends the application of sunscreen 2 mg/cm² every 2 hours.
- At least 4 market-image formulations should be tested including one formulation with permeation enhancer.

Master Key Elements for Sunscreen



- Demographics of subjects
 - Pilot study: To understand inter-subject and intra-subject variability
 - Pivotal study: Sufficient number of subjects representing general US demographics across sex, ages, and races.
- Body surface area
 - 75% body surface area is considered as the maximal skin area for sunscreen.
- Frequency of application
 - Every 2 hours per day (4 applications per 8 hours)
- Treatment duration
 - 5 days or to achieve steady state

Regulatory action and advice

- Publication of Proposed Rule, Sunscreen Drug Products for Over-the-Counter Human use (02/26/2019)
- Publication of guidance, Maximal usage trial (MUsT) for Topical Active ingredients being considered for inclusion in an over-the-counter monograph: Study elements and considerations (Draft 05/21/2018, Final 02/2019)

Article	
Maximal Usage Trial: An Overview of the Design of Systemic Bioavailability Trial for Topical Dermatological Products	Therapeutic Invovation a Regulatory Science O The Autorchy 2014 Reprints and permission: Autorchy DOI: 10.1177/2146479014539157 drs.agepub.com
Edward Dennis Bashaw, Pharm. D ¹ , Doanh C. Tran, Ph.D ¹ , Chinmay G. Shukla, Ph.D ¹ , and Xiaomei Liu, Pharm. D ¹	
	DIA
In Vitro Skin Permeation Methodology for Over-The-Counter Topical Dermatologic Products	Therapeutic Innovation & Regulatory Science 10 The Andron (2019) 20 The Andropeutic Andron (2019) 20 The Andron (2019) 20 The Andron (2019) 20 The Andropeutic Andron (2019) 20 The Andropeutic Andron (2019) 20 The Andron (2019) 20 The Andropeutic
Luke Oh, PhD ¹ , Sojeong Yi, PhD ¹ , Da Zhang, PhD ¹ , Soo Hyeon Shin, PhD ¹ , and Edward Bashaw, PharmD ¹ ®	

JAMA | Original Investigation

Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients A Randomized Clinical Trial

Murali K. Matta, PhD: Jeffry Florian, PhD: Robbert Zusterzeel, MD, PhD, MPH; Nageswara R. Pilli, PhD; Wlram Patel, PhD; Donna A. Volpe, PhD; Yang Yang, PhD; Luke Oh, PhD; Edward Bashaw, PharmD; Issam Zineh, PharmD, MPH; Carlos Sanabria, MD; Sarah Kemp, RN; Anthony Godfrey, PharmD; Steven Adah, PhD; Sergio Coelho, PhD; Jian Wang, PhD; Lesley-Anne Furlong, MD; Charles Ganley, MD; Theresa Michele, MD; David G. Strauss, MD, PhD

JAMA | Preliminary Communication

Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients A Randomized Clinical Trial

Murali K. Matta. PhD; Robbert Zusterzeel, MD, PhD, MPH; Nageswara R. Pilli, PhD; Vikram Patel, PhD; Donna A. Volpe, PhD; Jeffry Florian, PhD; Luke Oh, PhD; Edward Bashaw, PharmD; Issam Zineh, PharmD, MPH; Carlos Sanabria, MD; Sarah Kenng, RN; Anthony Godfrey, PharmD; Steven Adah, PhD; Sergio Coelho, PhD; Jan Wang, PhD; Lesley-Anne Furlong, MD; Charles Ganley, MD; Theresa Michele, MD; David G, Strauss, MD, PhD

Summary

- With the final rule deferral, 8 sunscreen active ingredients have been proposed for evaluation within a MUsT program by an industry trade group.
- Master MUsT protocol is
 - To standardize the MUsT study design elements.
 - To develop topical OTC product in a time- and budget- efficient manner.
- There are key elements for Sunscreen Master protocol: dose and dosing regimen, BSA, and treatment duration.
- The FDA encourages the industry to discuss both pilot and pivotal study design with the FDA prior to the initiation of the study.



Acknowledgements

Office of Clinical Pharmacology Edward D. Bashaw, PharmD

Division of Inflammatory and Immune Pharmacology Sojeong Yi, PhD Soo Hyeon Shin, PhD Da Zhang, PhD Chinmay Shukla, PhD Suresh Doddapaneni, PhD Chandrahas Sahajwalla, PhD

